Pure Global
NCT06421740

An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China

REal-world Utilization and Treatment Target ACHievement With Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis in China
AbbVie·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atopic Dermatitis
Study type
Observational
Sponsor & location
Primary sponsor
AbbVie
Timeline & enrollment
Phase
N/A
Start date
May 20, 2024
End date
Jun 30, 2026
Enrollment
1000 participants
Primary outcome

Number of participants with a dose change,Number of participants with interruption or permanent discontinuation,Number of participants with Upadacitinib drug compliance

Summary

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to
 inflammation of the skin.
 
 Upadacitinib is an approved drug for treating AD. Approximately 1000 adolescents and adult
 participants who are prescribed upadacitinib by their physician in accordance with local
 label will be enrolled in up to 40 sites in China.
 
 Participants will receive oral upadacitinib tablets as prescribed by their physician
 according to their routine clinical practice and local label. Participants will be followed
 up for approximately 12 months.
 
 There is expected to be no additional burden for participants in this trial. Participants
 will attend regular visits during the study at a hospital or clinic according to their
 routine clinical practice.

ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06421740
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06421740 through Pure Global AI's free database. This phase not specified trial is sponsored by AbbVie and is currently Not yet recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 1000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.